CORMRA
Development of carbon monoxide releasing molecules for the treatment of rheumatoid arthritis
| Coordinatore | "Alfama - Investigacao e Desenvolvimento de Produtos Farmaceuticos, Lda."
Organization address
address: "Av. da Republica, Quinta do Marques, Estacao Agronomica Nacional IBET/ITQB, Lab.7.14" contact info |
| Nazionalità Coordinatore | Portugal [PT] |
| Totale costo | 1˙424˙000 € |
| EC contributo | 1˙100˙000 € |
| Programma | FP7-SME
Specific Programme "Capacities": Research for the benefit of SMEs |
| Code Call | FP7-SME-2008-1 |
| Funding Scheme | BSG-SME |
| Anno di inizio | 2009 |
| Periodo (anno-mese-giorno) | 2009-11-01 - 2011-10-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
"Alfama - Investigacao e Desenvolvimento de Produtos Farmaceuticos, Lda."
Organization address
address: "Av. da Republica, Quinta do Marques, Estacao Agronomica Nacional IBET/ITQB, Lab.7.14" contact info |
PT (Oeiras) | coordinator | 475˙500.00 |
| 2 |
Micron Research Service
Organization address
address: Largo della Fiera 10 contact info |
IT (Venturina (Livorno)) | participant | 359˙500.00 |
| 3 |
Frimorfo SA
Organization address
city: Fribourg contact info |
CH (Fribourg) | participant | 209˙500.00 |
| 4 |
ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRLU
Organization address
address: VIA FIORENTINA 151 contact info |
IT (SIENA) | participant | 45˙000.00 |
| 5 |
INSTITUTO DE MEDICINA MOLECULAR
Organization address
address: AVENIDA PROF EGAS MONIZ contact info |
PT (LISBOA) | participant | 3˙500.00 |
| 6 |
Swiss BioQuant AG
Organization address
address: Christoph Merian-Ring 29a contact info |
CH (Reinach) | participant | 3˙500.00 |
| 7 |
UNIVERSITA DEGLI STUDI DI CATANIA
Organization address
address: PIAZZA UNIVERSITA 2 contact info |
IT (CATANIA) | participant | 3˙500.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The project will focus on the pre-clinical development of carbon monoxide releasing molecules (CORMs) for the treatment of rheumatoid arthritis (RA). Carbon monoxide (CO) has been shown, by several renowned laboratories around the world, to have a number of anti-inflammatory properties which turn it into an exceptionally promising compound against chronic inflammatory diseases such as RA. In its gaseous form CO will hardly be applicable as a drug in a clinical setting. One proponent SME, has conceived and produced a large number of molecules which will release or donate CO, inside the organism, in specific physiological or pathological conditions. These molecules, called CORMs, hold the promise of delivering CO in controlled amounts, at specific rates and in a targeted manner to inflamed tissues such as arthritic joints. In recent months some of these CORMs have been tested in preliminary experiments using rodent models of RA, and have yielded encouraging results in terms of efficacy and toxicity. The main goal of this project will be: to select a small number of exceptionally promising CORMs for the treatment of RA, to develop the best formulations for those compounds, to test their detailed pharmacological and toxicological properties, and ultimately arrive at one lead candidate for clinical development. With this aim, three different SMEs will join their resources, critical mass and knowledge in the field of CORMs, pharmacological test, analysis and standardization and validation of developed assays to gain the ambitious, but reasonable goal: at least one new molecule in clinical trials.'